Factor Xa Inhibitor [EPC]

Known as: Factor 10a Inhibitor, Activated Factor X Inhibitor, Activated Factor 10 Inhibitor 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
The majority of embolisms associated with atrial fibrillation (AF) are from the left atrial appendage (LAA). To treat the… (More)
  • figure 1
  • figure 2
Is this relevant?
2015
2015
We report on a 72-year-old male patient who developed a nontraumatic spinal subdural hematoma (SSDH) during rivaroxaban therapy… (More)
  • figure 2
  • figure 1
Is this relevant?
2015
2015
INTRODUCTION Patients with atrial fibrillation undergoing percutaneous coronary intervention may require combination therapy with… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2015
2015
Management of intracoronary thrombus in patients presenting more than 12 hours after the onset of ST elevation myocardial… (More)
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2014
Highly Cited
2014
OBJECTIVES The aim of this study was to determine the risk of major clinical and thromboembolic events after cardioversion for… (More)
  • table 1
  • table 2
Is this relevant?
2014
2014
Edoxaban, an oral direct factor Xa inhibitor, has proven antithrombotic efficacy. In a multicenter, phase II study, 264 total hip… (More)
  • table 1
  • table 2
Is this relevant?
2014
2014
Rivaroxaban is an oral factor Xa inhibitor used for stroke prevention in atrial fibrillation. There are currently no evidence… (More)
  • figure 1
Is this relevant?
2013
2013
OBJECTIVES The aim of this study was to determine if rivaroxaban is associated with a reduction in stent thrombosis among… (More)
  • table 1
  • figure 1
  • figure 3
  • figure 2
  • figure 4
Is this relevant?
2013
2013
BACKGROUND Apixaban is an oral, selective, direct factor Xa inhibitor approved for thromboprophylaxis after orthopedic surgery… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2013
2013
BACKGROUND Accelerated vascular calcification and increased risk of calciphylaxis can be a reason to restrict the use of vitamin… (More)
  • table 1
  • table 2
Is this relevant?